Gilead to Acquire Arcellx for $7.8B in Cash and CVRs, Offering 68% Premium

summarizeSummary

Gilead Sciences will acquire Arcellx for $7.8 billion, offering $115.00 per share in cash plus a $5.00 CVR, representing a 68% premium and full control over the promising anito-cel CAR T-cell therapy.

check_boxKey Events

• Acquisition Agreement Announced

  Gilead Sciences, Inc. will acquire Arcellx, Inc. for $115.00 per share in cash at closing and one contingent value right (CVR) of $5.00 per share, representing an implied equity value of $7.8 billion.

• Significant Premium Offered

  The offer price represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026.

• Contingent Value Right (CVR)

  A $5.00 CVR is payable upon the achievement of cumulative global net sales of anito-cel of at least $6.0 billion from launch through year-end 2029.

• Strategic Rationale for Acquisition

  Gilead gains full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma, accelerating its development and commercialization.

auto_awesomeAnalysis

This definitive agreement for Gilead to acquire Arcellx represents a transformational event for Arcellx shareholders. The offer of $115.00 per share in cash, plus a contingent value right (CVR) of $5.00 per share, implies a substantial 68% premium to Arcellx's 30-day volume-weighted average share price. The total implied equity value of $7.8 billion is more than double Arcellx's current market capitalization, indicating a significant re-rating of the company's value, especially as the stock is currently trading near its 52-week high. The acquisition builds on an existing collaboration for anito-cel, a key CAR T-cell therapy, and provides Gilead with full control, accelerating its development and commercialization. The CVR offers additional upside tied to anito-cel's cumulative global net sales reaching $6 billion by year-end 2029. The deal has unanimous board approval and support from key shareholders, increasing the likelihood of successful completion. The termination of the ATM program removes a potential source of future dilution.